Skip to main content
Andrew Kuykendall, MD, Oncology, Tampa, FL

AndrewTuckerKuykendallMD

Oncology Tampa, FL

Hematologic Oncology

Assistant Member, Department of Malignant Hematology

Overview of Dr. Kuykendall

Dr. Andrew Kuykendall is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and James A. Haley Veterans' Hospital-Tampa. He received his medical degree from University of Florida College of Medicine and has been in practice 5 years. He is one of 170 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 50 doctors at James A. Haley Veterans' Hospital-Tampa who specialize in Oncology. He has more than 80 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2015 - 2018
  • University of South Florida Morsani
    University of South Florida MorsaniResidency, Internal Medicine, 2012 - 2015
  • University of Florida College of Medicine
    University of Florida College of MedicineClass of 2012

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2014 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
    Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
    Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
    Andrew T Kuykendall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

  • Systemic Mastocytosis: Information for Patients and Caregivers
    Systemic Mastocytosis: Information for Patients and CaregiversAugust 26th, 2024
  • Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
    Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK InhibitorDecember 1st, 2022
  • Four of a Kind?
    Four of a Kind?May 1st, 2021